



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 55860

Title: Successful treatment of plasma exchange-refractory thrombotic thrombocytopenic purpura with rituximab: A case report and literature review

Reviewer's code: 03645108

Position: Peer Reviewer

Academic degree: FCCP, MD, PhD

Professional title: Associate Professor, Senior Researcher

Reviewer's Country/Territory: France

Author's Country/Territory: China

Manuscript submission date: 2020-04-13

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-04-14 11:38

Reviewer performed review: 2020-04-26 01:59

Review time: 11 Days and 14 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

Thrombotic thrombocytopenic purpura is a subtype of thrombotic microangiopathy, and characterized by microangiopathic hemolytic anemia and thrombocytopenia with or without neurological symptoms, renal damage, and fever. Its pathological features include severe diffuse thrombotic microangiopathy, MAHA, platelet consumption, and extensive microthrombus formation. Lesions can occur in multiple organs, such as the kidney and central nervous system. The typical clinical manifestations of TTP are thrombocytopenic purpura, MAHA, central nervous system symptoms, fever, and renal damage. Some patients may suffer from the first three symptoms only. TTP has an acute onset and rapid progression, and misdiagnosis and missed diagnosis often occur. The fatality rate is very high if there is no timely diagnosis and treatment. In this manuscript, the authors reported a case of TTP refractory to plasma exchange, which was later successfully treated with rituximab. This case is rare, and interesting. The case presentation is good, and very detail. The discuss of this case is acceptable. Figure of the patient's laboratory examination and temperature is interesting and useful, but images are small. Please update the images. Overall, this manuscript is very well written. I have no other specific comments.



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 55860

Title: Successful treatment of plasma exchange-refractory thrombotic thrombocytopenic purpura with rituximab: A case report and literature review

Reviewer's code: 02908908

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Professor

Reviewer's Country/Territory: Taiwan

Author's Country/Territory: China

Manuscript submission date: 2020-04-13

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-04-13 13:19

Reviewer performed review: 2020-04-26 02:02

Review time: 12 Days and 12 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

A very interesting case of the plasma exchange-refractory thrombotic thrombocytopenic purpura with rituximab. The case is rare. The manuscript is very well written. Only some minor language editing is required.